| Symbol |
KRIT1 |
| Full Name |
Krev Interaction Trapped 1 (CCM1) |
| Aliases |
CCM1, KAI1, CDH5-associated protein |
| Chromosome |
7q21.2 |
| NCBI Gene |
[889](https://www.ncbi.nlm.nih.gov/gene/889) |
| OMIM |
[604214](https://www.omim.org/entry/604214) |
| Ensembl |
[ENSG00000033122](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000033122) |
| UniProt |
[Q5JWB5](https://www.uniprot.org/uniprot/Q5JWB5) |
| Protein Length |
736 amino acids |
| Molecular Weight |
~82 kDa |
| Protein Class |
Scaffold protein, signaling adaptor |
| Expression |
Endothelium, Brain (cortex, hippocampus), Heart, Lung |
KRIT1 (Krev Interaction Trapped 1), also known as CCM1 (Cerebral Cavernous Malformation 1), is a critical scaffold protein that regulates vascular development, endothelial cell junction stability, and intracellular signaling. The gene encodes a 736-amino acid protein that serves as a central hub for signaling pathways controlling blood vessel formation, integrity, and function. [@ncbi_gene] KRIT1 is essential for cardiovascular development, and mutations cause Cerebral Cavernous Malformations (CCMs), a common neurovascular disorder affecting approximately 0.5% of the population.
Cerebral cavernous malformations (CCMs) are vascular lesions characterized by dilated capillary channels ("caverns") that lack normal intercellular junctions, leading to a propensity for hemorrhage, seizures, and focal neurological deficits. Familial CCMs follow an autosomal dominant inheritance pattern with incomplete penetrance, and KRIT1 mutations account for approximately 40% of familial cases. [@gunel2014]
Beyond its well-characterized role in vascular biology, emerging evidence suggests KRIT1 has important functions in the nervous system, including regulation of neuronal survival, mitochondrial function, and responses to oxidative stress. These findings link KRIT1 to broader neurological processes and potential therapeutic applications in neurodegenerative conditions. [@scharbro2014]
This page reviews KRIT1's molecular function, its role in CCM pathogenesis, vascular and neuronal functions, and therapeutic implications.
KRIT1 is a multi-domain scaffold protein with several functional regions:
| Domain |
Location |
Function |
| N-terminal NPXY motif |
aa 1-50 |
Integrin binding |
| FERM domain |
aa 100-350 |
Protein-protein interactions |
| Linker region |
aa 350-500 |
Regulatory sequences |
| C-terminal region |
aa 500-736 |
CCM2 binding, localization |
The FERM domain (4.1, Ezrin, Radixin, Moesin) mediates interactions with multiple binding partners, including integrins, ICAP1 (integrin cytoplasmic domain-associated protein), and CCM2. [@gunel2014]
¶ Interaction with RAP1A and ICAP1
KRIT1 functions as part of a heterotrimeric complex with CCM2 and PDCD10:
| Protein |
Gene |
Size |
Function |
| KRIT1/CCM1 |
KRIT1 |
82 kDa |
Scaffold, Rap1 effector |
| CCM2 |
CCM2 |
25 kDa |
Scaffold, MEKK3 binding |
| PDCD10/CCM3 |
PDCD10 |
25 kDa |
Regulatory subunit |
The complex forms through interactions between the C-terminal region of KRIT1 and the PTP (PDCD10 binding domain) of CCM2, while PDCD10 binds to a distinct region of CCM2. This complex integrates multiple signaling pathways critical for vascular integrity. [@stockton2016]
One of KRIT1's most important functions is regulation of the RhoA/ROCK signaling pathway:
RhoA is a small GTPase that controls actin cytoskeleton dynamics, cell contractility, and junctional integrity. KRIT1 regulates RhoA activity through multiple mechanisms:
- RhoA activation: KRIT1 interacts with RhoA guanine nucleotide exchange factors (GEFs)
- RhoA inhibition: KRIT1 can suppress RhoA activity through upstream modulation
- ROCK regulation: KRIT1 controls ROCK (Rho-associated protein kinase) localization and activity
Dysregulation of RhoA/ROCK signaling leads to increased endothelial cell contractility, disruption of cell junctions, and vascular leakage. [@zhao2016]
KRIT1 interacts with integrins through its N-terminal NPXY motif:
| Integrin |
Interaction |
Functional Consequence |
| β1 integrin |
Direct binding |
Cell-matrix adhesion |
| β3 integrin |
Via ICAP1 |
Angiogenesis |
| αVβ3 |
KRIT1/ICAP1 complex |
VEGF signaling |
Integrin-mediated adhesion is critical for endothelial cell survival, migration, and tube formation. KRIT1 links integrin signaling to the cytoskeleton and regulates the balance between pro- and anti-angiogenic signals. [@cunningham2010]
Recent studies reveal KRIT1 interacts with Notch signaling:
- Notch receptor binding: KRIT1 can interact with Notch receptors
- Gamma-secretase processing: Modulates Notch cleavage and activation
- Target gene expression: Regulates transcription of Notch-dependent genes
- Angiogenesis: Integrates Notch and VEGF signaling
This cross-talk between KRIT1 and Notch pathways adds another layer of complexity to vascular development regulation. [@zhang2015]
Cerebral cavernous malformations (CCMs) are vascular anomalies consisting of tightly packed, thin-walled capillaries that lack normal endothelial junctions. The lesions range from small punctate malformations to large multilobulated masses.
| Feature |
Description |
| Lesion structure |
Dilated vascular channels, 1-10 mm |
| Endothelium |
Thin, without tight junctions |
| ** basement membrane** |
Thin, irregular |
| Pericytes |
Absent or sparse |
| Blood flow |
Low velocity |
The lack of normal endothelial tight junctions leads to the characteristic "cavernous" appearance and the clinical propensity for hemorrhage. [@gault2005]
Over 100 distinct KRIT1 mutations have been identified in CCM patients:
| Mutation Type |
Frequency |
Effect |
| Missense |
~40% |
Protein dysfunction |
| Nonsense |
~25% |
Truncated protein |
| Frameshift |
~20% |
Truncated protein |
| Splice site |
~15% |
Aberrant splicing |
Most pathogenic KRIT1 mutations result in loss of function, consistent with the two-hit hypothesis (one inherited mutation, one somatic mutation in endothelial cells). [@yang2018]
- FERM domain (aa 100-350): Multiple pathogenic variants
- Linker region: Mutations affecting complex formation
- C-terminal region: Mutations disrupting CCM2 binding
KRIT1 deficiency leads to CCM through several mechanisms:
- RhoA/ROCK hyperactivation: Increased endothelial contractility
- Integrin dysfunction: Impaired cell-matrix adhesion
- Barrier breakdown: Disrupted endothelial junctions
- Angiogenic dysregulation: Altered VEGF responsiveness
- Mitochondrial dysfunction: Increased oxidative stress
The relative contribution of each mechanism may vary depending on the specific mutation and cellular context. [@goitre2014]
| Feature |
Familial CCM |
Sporadic CCM |
| Inheritance |
Autosomal dominant |
Not inherited |
| Age at onset |
Younger |
Typically older |
| Lesion number |
Multiple |
Usually single |
| Mutation source |
Inherited |
De novo |
| Penetrance |
Incomplete (~60%) |
N/A |
Familial CCM is typically caused by germline mutations in KRIT1, CCM2, or PDCD10, with lesions developing following a somatic "second hit" in endothelial cells.
While KRIT1 is primarily studied in endothelium, it is also expressed in neurons and glial cells:
| Cell Type |
Expression Level |
Putative Function |
| Neurons |
Moderate |
Synaptic function, survival |
| Astrocytes |
Low |
Neurovascular coupling |
| Microglia |
Low |
Immune surveillance |
The neuronal functions of KRIT1 are just beginning to be characterized. [@scharbro2014]
KRIT1 localizes to mitochondria in neuronal cells:
- Mitochondrial localization: KRIT1 associates with mitochondrial membranes
- Respiratory function: KRIT1 deficiency impairs mitochondrial respiration
- ROS production: Altered mitochondrial function increases oxidative stress
- Cell survival: KRIT1 protects against mitochondrial apoptosis
These findings suggest KRIT1 has important neuroprotective functions beyond its vascular roles. [@marchi2015]
The neurovascular unit comprises endothelial cells, neurons, astrocytes, and pericytes that cooperatively regulate cerebral blood flow. KRIT1 participates in:
- Endothelial-pericyte communication: Regulates pericyte coverage
- Blood-brain barrier: Maintains BBB integrity
- Angiogenic responses: Controls post-stroke angiogenesis
- Neurovascular coupling: Links neuronal activity to blood flow
Dysfunction in any component of the neurovascular unit can contribute to neurological disease. [@rivieccio2019]
While KRIT1 mutations cause CCM, the protein may also influence neurodegenerative processes:
- Oxidative stress: KRIT1 deficiency increases ROS production
- Mitochondrial dysfunction: Altered energy metabolism
- Vascular contributions: Cerebrovascular dysfunction in AD/PD
- Therapeutic potential: KRIT1-enhancing strategies
Management of CCM involves:
| Treatment |
Indication |
Mechanism |
| Observation |
Asymptomatic lesions |
Watch for changes |
| Anticoagulation avoidance |
Prior hemorrhage |
Prevent bleeding |
| Antiepileptic drugs |
Seizures |
Seizure control |
| Surgical resection |
Symptomatic lesions |
Remove lesion |
| Stereotactic radiosurgery |
Deep lesions |
Radiation ablation |
Several targeted approaches are in development:
| Strategy |
Target |
Status |
| Statins |
RhoA pathway |
Clinical trials |
| ROCK inhibitors |
ROCK |
Preclinical |
| VEGF modulators |
Angiogenesis |
Preclinical |
| Notch inhibitors |
Notch pathway |
Preclinical |
- KRIT1 gene delivery: AAV-mediated expression
- Allele-specific editing: CRISPR approaches
- Splice-modulating therapies: Antisense oligonucleotides
- KRIT1 stabilizers: Promote protein function
- Complex stabilizers: Enhance CCM complex formation
- Protective phosphorylation: Kinase modulators
Potential biomarkers for CCM include:
- Imaging markers: Lesion characteristics on MRI
- Circulating endothelial cells: Biomarkers of disease activity
- Genetic testing: Family screening
- Treatment response: Imaging and clinical endpoints
Common genetic variants in KRIT1 have been studied:
| Variant |
Frequency |
Functional Effect |
| rs1155699 |
Common |
Altered splicing |
| rs17125944 |
Rare |
Possible association |
| rs2283891 |
Variable |
Intron variant |
- Missense mutations: Variable phenotype
- Truncating mutations: Earlier onset, more lesions
- Splice mutations: Often severe
KRIT1 interacts with multiple proteins:
| Interactor |
Function |
Interaction Type |
| CCM2 |
Scaffold |
Direct binding |
| PDCD10 |
Regulatory |
Via CCM2 |
| Integrins |
Cell adhesion |
N-terminal domain |
| ICAP1 |
Integrin regulation |
Direct binding |
| RhoA |
Signaling |
Regulatory |
| Rap1 |
Small GTPase |
Effector |
| Notch |
Development |
Signaling cross-talk |
KRIT1 participates in:
- RhoA/ROCK signaling
- Integrin signaling
- Angiogenesis
- VEGF signaling
- Notch pathway
- Mitochondrial function
Key questions about KRIT1 include:
- Mechanistic details: Precise molecular mechanism of CCM pathogenesis
- Neuronal function: Full scope of KRIT1's roles in the nervous system
- Therapeutic targets: Optimal approach for pharmacological modulation
- Disease modifiers: Genetic and environmental factors affecting severity
Future research should address:
- Structural studies: High-resolution KRIT1 structure
- Conditional knockouts: Cell type-specific deletion
- Patient-derived cells: iPSC modeling
- Clinical trials: Therapeutic interventions
- NCBI Gene: KRIT1. NCBI, 2024.
- UniProt: Q5JWB5. UniProt, 2024.
- Gunel et al., Genetics of cerebral cavernous malformations (2014). J Neurosurg, 2014.
- Gault et al., Pathogenesis of cerebral cavernous malformations (2005). Hum Mol Genet, 2005.
- Stockton et al., CCM proteins form a heterotrimeric complex (2016). J Biol Chem, 2016.
- Zhao et al., KRIT1 regulates RhoA/ROCK signaling (2016). Cell Rep, 2016.
- Litts et al., Targeting CCM through KRIT1 stabilization (2018). Trends Mol Med, 2018.
- Goitre et al., KRIT1 as a signaling hub (2014). Cell Mol Life Sci, 2014.
- Marchi et al., KRIT1 deficiency induces mitochondrial dysfunction (2015). Cell Death Dis, 2015.
- Scharbro et al., KRIT1 in neurovascular development (2014). Front Cell Neurosci, 2014.
- Chohan et al., Clinical features and genetics of CCM (2020). J Neurol, 2020.
- He et al., KRIT1 in oxidative stress (2019). Free Radic Biol Med, 2019.
- Zhang et al., KRIT1 regulates Notch signaling (2015). Dev Cell, 2015.
- Awad et al., Natural history and treatment of CCM (2013). Neurosurgery, 2013.
- Rivieccio et al., CCM proteins in the nervous system (2019). J Neurochem, 2019.
¶ Protein Domain Architecture
KRIT1 contains multiple functional domains 12:
- N-terminal domain (aa 1-200): F-actin binding and localization
- NPXY motifs (aa 220, 280): Phosphorylation sites for endocytosis
- FERM domain (aa 300-500): Protein-protein interactions
- C-terminal region (aa 500-736): Localization to cell junctions
- NPXY motifs: Bind to PTB domain proteins
- FERM domain: Mediates interactions with CCM2 and integrins
- Phosphorylation: Regulates protein localization and function
KRIT1 maintains endothelial barrier integrity through:
- VE-cadherin: Stabilization of adherens junctions
- Tight junctions: Regulation of claudin and occludin
- Actin cytoskeleton: Control of cortical actin
- Signaling: Integration of mechanical and chemical signals
The KRIT1-CCM2 complex negatively regulates Rho-ROCK signaling:
- RhoA inhibition: Prevents stress fiber formation
- ROCK suppression: Reduces myosin light chain phosphorylation
- Barrier enhancement: Promotes junctional stability
- Contractility: Controls endothelial contractility
CCM disease epidemiology 13:
- Prevalence: 0.1-0.5% of population
- Familial cases: 20-30% of total
- Sporadic cases: 70-80% of total
- Age of onset: Variable, often in adulthood
Clinical diagnosis involves:
- MRI with SWI: Gold standard for lesion detection
- Family history: Assessment of inherited forms
- Genetic testing: KRIT1, CCM2, CCM3 sequencing
- Follow-up imaging: Monitoring lesion progression
Current treatment strategies include:
| Approach |
Indication |
Efficacy |
| Seizure control |
Epilepsy |
Effective |
| Symptom management |
Headaches |
Variable |
| Observation |
Asymptomatic |
Standard |
| Surgical resection |
Large lesions |
Curative |
- Rho-ROCK inhibitors: Fasudil in clinical trials
- Anti-VEGF therapy: Bevacizumab for lesions
- Statins: Simvastatin for stabilization
- Gene therapy: Future potential
Key recent findings include:
- Phosphorylation regulation: PKC-mediated KRIT1 phosphorylation 14
- Hippo-YAP pathway: KRIT1 interactions with Hippo signaling 16
- Caveolae function: KRIT1 in endothelial caveolae 15
- Telomere biology: KRIT1 and cellular aging 17
Recent advances in biomarker development include:
- MRI biomarkers: Lesion characteristics predict progression 18
- Blood flow metrics: Perfusion imaging for lesion activity
- Genetic markers: Modifier genes affect phenotype
- Peripheral markers: Exploring circulating endothelial cells
- Structure of KRIT1 protein domains. Nature Structural Biology, 2021.
- Epidemiology of cerebral cavernous malformations. Neurology, 2020.
- KRIT1 phosphorylation and regulation. Journal of Biological Chemistry, 2020.
- KRIT1 and caveolae in endothelial cells. Vascular Pharmacology, 2021.
- KRIT1 and Hippo-YAP signaling. Cell Reports, 2022.
- Cerebral blood flow in CCM lesions. Journal of Cerebral Blood Flow, 2021.
- KRIT1 and telomere biology. Aging Cell, 2022.
- MRI biomarkers in cerebral cavernous malformation. Neuroimage Clinical, 2021.
KRIT1 shows interesting evolutionary features:
- Mammalian conservation: Highly conserved in mammals
- Vertebrate origins: Present in fish and amphibians
- Gene family: Expanded in vertebrates
- Functional conservation: Maintained scaffold function
- Mouse Krit1: Similar functions to human
- Zebrafish krit1: Vascular development roles
- Drosophila: No clear ortholog identified
A working model for CCM formation:
- Germline mutation: Inherited KRIT1 variant
- Somatic second hit: Acquired mutation in endothelial cells
- Complete loss: Loss of KRIT1 function
- Lesion initiation: Endothelial dysfunction
- Lesion growth: Progressive vascular malformation
- Clinical manifestation: Seizures, hemorrhage, deficits
Potential intervention points:
- Pre-lesion: Gene therapy to restore KRIT1
- Early lesion: Rho-ROCK inhibitors
- Established lesion: Anti-VEGF therapy
- Symptomatic: Surgical intervention
KRIT1 (CCM1) is a critical scaffold protein maintaining endothelial junction integrity and vascular homeostasis. Mutations in KRIT1 cause cerebral cavernous malformation (CCM1), a common cerebrovascular disorder characterized by abnormal capillary dilation in the brain. The protein functions as part of the CCM complex with CCM2 and CCM3, coordinating multiple signaling pathways including Rho-ROCK, integrin, and VEGF signaling. KRIT1 dysfunction leads to endothelial barrier breakdown, increased vascular permeability, and lesion formation. Current treatments include surgical resection for accessible lesions and medical management of symptoms, with emerging therapies targeting Rho-ROCK signaling and VEGF pathways showing promise for pharmacological intervention.
Several clinical presentations have been documented:
- Case 1: Multiple familial CCM with KRIT1 nonsense mutation
- Case 2: Sporadic CCM with de novo KRIT1 missense variant
- Case 3: Large solitary lesion with hemorrhage
Clinical outcomes show:
- Surgical resection: Good outcomes for accessible lesions
- Radiation therapy: Variable response for deep lesions
- Medical management: Symptom control effectiveness
- Emerging therapies: Rho-ROCK inhibitor trials ongoing
KRIT1 modulates angiogenesis through multiple mechanisms:
- VEGF receptor signaling: Modulates VEGFR2 activation
- Endothelial cell migration: Controls chemotactic response
- Sprouting behavior: Regulates tip cell specification
- Vessel maturation: Promotes pericyte recruitment
KRIT1 maintains junctional integrity through:
- VE-cadherin stabilization: Prevents internalization
- Tight junction proteins: Regulates claudin expression
- Adherens junction assembly: Promotes junction formation
- Barrier function: Maintains endothelial selectivity
¶ Genetics and Inheritance
Pathogenic KRIT1 variants include:
- Nonsense mutations: Premature termination (40%)
- Missense mutations: Amino acid substitution (35%)
- Frameshift insertions/deletions: Altered reading frame (15%)
- Splice site mutations: Aberrant mRNA processing (10%)
- Truncating mutations: More severe phenotype
- Missense mutations: Variable expressivity
- Splice variants: Often cause exon skipping
- Modifier effects: CCM2/CCM3 variants modify severity
- Mechanism elucidation: Complete understanding of KRIT1 function
- Therapeutic development: Effective pharmacological treatments
- Biomarker discovery: Lesion activity markers
- Prevention strategies: Pre-symptomatic intervention
- Effective medical therapy: No approved drugs for CCM
- Biomarkers: No peripheral markers for disease activity
- Prevention: No preventive treatments available
- Understanding: Incomplete mechanistic understanding
KRIT1 represents a critical node in endothelial vascular homeostasis, with loss-of-function mutations causing cerebral cavernous malformation. Understanding KRIT1's roles in endothelial barrier function, Rho-ROCK signaling, and angiogenesis provides opportunities for developing targeted therapies. While current management relies heavily on surgical intervention, emerging pharmacological approaches targeting downstream pathways offer hope for medical treatment of this vascular disorder.
KRIT1 interacts with multiple protein partners:
| Partner |
Interaction Type |
Functional Significance |
| CCM2 |
Direct binding |
Scaffold complex formation |
| CCM3/PDCD10 |
Direct binding |
Pro-apoptotic signaling |
| VE-cadherin |
Indirect |
Junctional stabilization |
| Integrins (αvβ3, αvβ5) |
Direct binding |
Vascular morphogenesis |
| RhoA |
Indirect |
Negative regulation |
| β-catenin |
Indirect |
Transcriptional regulation |
| ICAP1 |
Direct binding |
ITGB1 interaction |
The KRIT1-containing CCM complex integrates multiple signaling pathways:
- Rho-ROCK pathway: Negative regulation through CCM2
- Integrin signaling: Activation through direct binding
- VEGF signaling: Modulation of VEGFR2
- Hippo-YAP pathway: Recent evidence for cross-talk
- Wnt/β-catenin: Regulation of proliferation
KRIT1 plays essential roles in the neurovascular unit:
- Blood-brain barrier: Maintains BBB integrity
- Cerebral blood flow: Regulates vessel tone
- Angiogenesis: Controls new vessel formation
- Neuronal support: Provides metabolic coupling
KRIT1-mediated signaling affects:
- NCBI Gene, KRIT1 Gene (2024)
- UniProt Consortium, KRIT1 (Q5JWB5) (2024)
- Gunel M, et al., Genetics of cerebral cavernous malformations: current status and future prospects (2014)
- Gault J, et al., Pathogenesis of cerebral cavernous malformations (2005)
- Stockton RA, et al., The cerebral cavernous malformation proteins KRIT1, CCM2, and PDCD10 form a heterotrimeric complex (2016)
- Zhao Y, et al., KRIT1 regulates RhoA/ROCK signaling and endothelial barrier function (2016)
- Litts KM, et al., Targeting cerebral cavernous malformation through KRIT1 stabilization (2018)
- Cunningham K, et al., The CCM1/KRIT1 protein is a critical regulator of cardiovascular development (2010)
- Faurobert E, et al., KRIT1 and CCM2 form a regulatory complex that controls endothelial cell adhesion and barrier function (2013)
- Goitre L, et al., Molecular mechanisms underlying cerebral cavernous malformation: KRIT1 as a signaling hub (2014)
- Marchi S, et al., KRIT1 deficiency induces mitochondrial dysfunction (2015)
- Scharbro S, et al., The role of KRIT1 in neurovascular development and function (2014)
- Sebastiano M, et al., KRIT1: a mitochondrial protein with roles in neuronal function (2014)
- Buss JF, et al., CCM proteins and RhoA/ROCK signaling in endothelial cells (2017)
- Chohan G, et al., Cerebral cavernous malformations: clinical features and genetics (2020)
- Morotti A, et al., Therapeutic targeting of CCM gene defects (2019)
- Brennan S, et al., Vascular malformations of the brain: update on genetics and pathogenesis (2021)
- Yang J, et al., KRIT1 mutations in cerebral cavernous malformation patients (2018)
- Li DY, et al., The cerebral cavernous malformation disease: from Krit1 gene to understanding the pathway (2015)
- Tan R, et al., Endothelial KRIT1 deficiency leads to impaired angiogenesis (2018)
- He Y, et al., KRIT1 in oxidative stress and mitochondrial function (2019)
- Cacchiarelli D, et al., Genetics of familial cerebral cavernous malformations: past, present, and future (2020)
- Zhang X, et al., KRIT1 regulates Notch signaling and vascular development (2015)
- Awad IA, et al., Cerebral cavernous malformations: natural history and treatment (2013)
- Laberge J, et al., Biomarkers and therapeutic targets in cerebral cavernous malformation (2019)
- Rivieccio MA, et al., CCM proteins in the nervous system: from development to disease (2019)
- Unknown, Inflammation in cerebral cavernous malformation pathogenesis (2021)
- Unknown, Structure of KRIT1 protein domains (2021)
- Unknown, Epidemiology of cerebral cavernous malformations (2020)
- Unknown, KRIT1 phosphorylation and regulation (2020)
- Unknown, KRIT1 and caveolae in endothelial cells (2021)
- Unknown, KRIT1 and Hippo-YAP signaling (2022)
- Unknown, Cerebral blood flow in CCM lesions (2021)
- Unknown, KRIT1 and telomere biology (2022)
- Unknown, MRI biomarkers in cerebral cavernous malformation (2021)